ethyl 1-(2-oxo-2,3-dihydrobenzo[d]thiazol-6-ylsulfonyl)piperidine-2-carboxylate | 1432733-52-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 1-(2-oxo-2,3-dihydrobenzo[d]thiazol-6-ylsulfonyl)piperidine-2-carboxylate
• 英文别名: ethyl 1-[(2-oxo-3H-1,3-benzothiazol-6-yl)sulfonyl]piperidine-2-carboxylate
• CAS: 1432733-52-2
• 化学式: C₁₅H₁₈N₂O₅S₂
• 分子量: 370.45
• InChiKey: UGUFHLYZGISNLG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  127
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-哌啶甲酸乙酯 、 1,3-苯并噻唑-6-磺酰氯 在 N,N-二异丙基乙胺 作用下， 以91%的产率得到ethyl 1-(2-oxo-2,3-dihydrobenzo[d]thiazol-6-ylsulfonyl)piperidine-2-carboxylate
  参考文献：
  名称：

  [EN] FKBP SUBTYPE-SPECIFIC RAPAMYCIN ANALOGUE FOR USE IN TREATMENT OF DISEASES
  [FR] ANALOGUE DE LA RAPAMYCINE SPÉCIFIQUE DU SOUS-TYPE FKBP POUR UNE UTILISATION DANS LE TRAITEMENT DE MALADIES

  摘要：

  公开号：

  WO2013064703A9

文献信息

• Bicyclic aza-amides for treatment of psychiatric disorders
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：EP2690102A1

  公开（公告）日：2014-01-29

  The present invention relates to compounds of formula (I) having a bicyclic aza-amides scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said bicyclic aza-amides compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.

  本发明涉及具有双环氮代酰胺骨架的化合物（I）的公式，这些化合物的药用盐以及含有至少一种这些化合物的药用载体、赋形剂和/或稀释剂的药物组合物。所述的双环氮代酰胺化合物可用于预防和/或治疗精神障碍和神经退行性疾病、障碍和病况。
• [EN] BICYCLIC AZA-AMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS<br/>[FR] AZA-AMIDES BICYCLIQUES UTILISÉS DANS LE TRAITEMENT DES TROUBLES PSYCHIATRIQUES
  申请人：MAX PLANCK GESELLSCHAFT

  公开号：WO2014015993A1

  公开（公告）日：2014-01-30

  The present invention relates to compounds of formula (I) having a bicyclic aza-amides scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said bicyclic aza- amides compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.

  本发明涉及具有双环氮杂酰胺骨架的化合物（I）的公式，这些化合物的药用盐以及含有这些化合物之一的药用载体、赋形剂和/或稀释剂的药物组合物。所述的双环氮杂酰胺化合物可用于预防和/或治疗精神障碍和神经退行性疾病、障碍和症状。
• BICYCLIC AZA-AMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS
  申请人：MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.

  公开号：US20150183786A1

  公开（公告）日：2015-07-02

  The present invention relates to compounds of formula (I) having a bicyclic aza-amides scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said bicyclic aza-amides compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.

  本发明涉及具有双环氮杂酰胺支架的公式（I）化合物，这些化合物的药学上可接受的盐以及包含至少一种这些化合物与药学上可接受的载体、赋形剂和/或稀释剂的制药组合物。所述的双环氮杂酰胺化合物可用于预防和/或治疗精神障碍和神经退行性疾病、障碍和病况。
• Increasing the Efficiency of Ligands for FK506-Binding Protein 51 by Conformational Control
  作者：Yansong Wang、Alexander Kirschner、Anne-Katrin Fabian、Ranganath Gopalakrishnan、Christoph Kress、Bastiaan Hoogeland、Uwe Koch、Christian Kozany、Andreas Bracher、Felix Hausch

  DOI：10.1021/jm400087k

  日期：2013.5.23

  The design of efficient ligands remains a key challenge in drug discovery. In the quest for lead-like ligands for the FK506-binding protein 51 (FKBP51), we designed two new classes of bicyclic sulfonamides to probe the contribution of conformational energy in these ligands. The [4.3.1] scaffold had consistently higher affinity compared to the [3.3.1] or monocyclic scaffolds, which could be attributed to better preorganization of two key recognition motifs. Surprisingly, the binding of the rigid [4.3.1] scaffold was enthalpy-driven and entropically disfavored compared to the flexible analogues. Cocrystal structures at atomic resolution revealed that the sulfonamide nitrogen in the bicyclic scaffolds can accept an unusual hydrogen bond from Tyr(113) that mimics the putative FKBP transition state. This resulted in the first lead-like, functionally active ligand for FKBP51. Our work exemplifies how atom-efficient ligands can be achieved by careful conformational control even in very open and thus difficult binding sites such as FKBP51.
• US9371322B2
  申请人：——

  公开号：US9371322B2

  公开（公告）日：2016-06-21